Mallinckrodt (MNK) PT, Estimates Lowered at Leerink Partners Following Mixed Q3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Mallinckrodt plc Reports Fiscal 2015 Third Quarter Financial Results
August 4, 2015 6:55 AM EDTCHESTERFIELD, United Kingdom, Aug. 4, 2015 /PRNewswire/ --Â Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today reported results for the third quarter of fiscal 2015, which ended June 26, 2015.
Net sales were $965.1 million compared with $653.1 million in the third quarter of fiscal 2014, an increase of 47.8%. The increase was primarily driven by the inclusion in the company's portfolio of H.P. Acthar® Gel (repository corticotropin injection) and INOMAX® (nitric oxide) for... More
